Approximately 15% of the Norwegian adult population had an Lp(a) test between 2000 and 2023, including 1.5% of the population over 18 years in 2023 (64,875 Lp(a) measurements). Tests were primarily requested by GPs, and a family history of premature cardiovascular disease (CVD) was the major motivation for testing.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.